Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study

Jing, Z.-C.; Jiang, X.; Wu, B.-X.; Xu, X.-Q.; Wu, Y.; Ma, C.-R.; Wang, Y.; Yang, Y.-J.; Pu, J.-L.; Gao, W.
September 2009
Heart;Sep2009, Vol. 95 Issue 18, p18
Academic Journal
Background: Vardenafil is a new phosphodiesterase-5 inhibitor that has shown some efficacy in the treatment of pulmonary arterial hypertension (PAH). Objective: To examine the long-term effects of vardenafil in patients with PAH. Methods: A multicentre, open-label study of 1-year's duration was undertaken in 45 patients with PAH to determine the long-term safety and efficacy of vardenafil (5 mg once daily for the first 4 weeks, then 5 mg twice daily) and make a preliminary assessment of its monthly acquisition cost compared with other PAH-active treatments. The patients' clinical features, exercise capacity, WHO functional class and haemodynamic variables were measured at baseline and at 3 and at least 9 months after initiating vardenafil treatment. Results: At the 3 months and a mean (SD) of 14 (3) months (range 9-18) follow-up assessments, the 6 min walking distance was significantly increased from baseline by 70.7 (78.4) m (p<0.001) and 83.4 (91.8) m (p<0.001), respectively. Furthermore, long-term treatment with vardenafil for a mean duration of >1 year was also associated with improvements in haemodynamic parameters, WHO functional class and serum uric acid concentrations. Overall, vardenafil treatment was well tolerated. No patients were withdrawn owing to adverse events and none died during the course of the study. Conclusion: Long-term treatment with vardenafil is well tolerated and has sustained beneficial effects on PAH, as measured by patients' exercise capacity, WHO functional class and haemodynamic parameters.


Related Articles

  • Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Valerio, Christopher J.; Handler, Clive E.; Kabunga, Peter; Smith, Colette J.; Denton, Christopher P.; Coghlan, John G. // Rheumatology;Nov2010, Vol. 49 Issue 11, p2147 

    Objectives. To report outcomes in patients with CTD-pulmonary arterial hypertension (CTD-PAH) in an observational cohort treated with bosentan or sitaxentan and determine whether differences would justify a randomized, controlled multicentre study in this subpopulation.Methods. Patients with...

  • Current Pharmacological Treatment of Pulmonary Arterial Hypertension. Steiropoulos, Paschalis; Trakada, Georgia; Bouros, Demosthenes // Current Clinical Pharmacology;Jan2008, Vol. 3 Issue 1, p11 

    Pulmonary arterial hypertension (PAH) is a disease characterized by an elevation in pulmonary artery pressure that can lead to right ventricular failure and death. Conventional treatment is based on non-specific drugs (warfarin, oxygen, diuretics). Pure vasodilators like calcium channel...

  • Sitaxsentan. Reinhart, Kurt; White, C. Michael // Formulary;May2007, Vol. 42 Issue 5, p295 

    Elevated blood pressure in the pulmonary vasculature, known as pulmonary arterial hypertension (PAH), stresses the right side of the heart and can increase the risk for functional disability and death. In advanced disease, several drugs can be employed, including calcium-channel blockers,...

  • Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension. Attawadee SAE YOON; Somchai SAWATDEE; Chuthamas WORADECHAKUL; Kridsada SAE CHEE; Apichart ATIPAIRIN // Scientia Pharmaceutica;Oct-Dec2015, Vol. 83 Issue 4, p659 

    Sildenafil is a potent and selective phosphodiesterase-5 inhibitor that is effectively used in the treatment of pulmonary arterial hypertension. In several countries, hospital pharmacists prepare the drug in an extemporaneous liquid preparation as there are no liquid formulations available for...

  • Immediate and Long-term Hemodynamic and Clinical Effects of Sildenefil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. Bhatia, Sundeep; Frantz, Robert P.; Severson, Cathy J.; Durst, Louise A.; McGoon, Michael D. // Mayo Clinic Proceedings;Oct2003, Vol. 78 Issue 10, p1207 

    Determines the immediate and long-term effects of adding sildenefil, a phosphodiesterase-5 inhibitor to the medical regimen of patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator effect in patients already receiving vasodilators for PAH.

  • New insights into the treatment of pulmonary arterial hypertension. Clavecilla, Stella Q. // Formulary;Mar2003, Vol. 38 Issue 3, p150 

    Provides alternative insights into the treatment of pulmonary arterial hypertension. Etiology and pathophysiology; Diagnostic procedures; Disease management; Therapeutic considerations.

  • New way to treat pulmonary hypertension?  // Journal of Clinical Investigation;Jul2011, Vol. 121 Issue 7, p2529 

    An introduction to the journal is presented in which the editor provides new insight to treat pulmonary arterial hypertension (PAH).

  • Under pressure: A review of pulmonary hypertension and its treatments. Hinds, Karla // Drug Formulary Review;Aug2007 Supplement, Vol. 23, p1 

    The article focuses on the treatments of pulmonary hypertension. The author reports that idiopathic pulmonary arterial hypertension, a rare disorder, is associated with high morbidity and mortality. One to two people per million, usually those in the 20 to 30 year age range, are affected by...

  • Sildenafil enhances HRQOL in PAH.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p12 

    Presents information on a study which focused on the effectiveness of sildenafil in improving health-related quality of life (HRQOL) of patients with pulmonary arterial hypertension. Dosage of sildenafil; Use of the Short-Form 36 and the EuroQoL questionnaires in the study; Comment from...


Read the Article


Sign out of this library

Other Topics